PT - JOURNAL ARTICLE AU - Spencer B. Huggett AU - Jeffrey S. Hatfield AU - Joshua D. Walters AU - John E. McGeary AU - Justine W. Welsh AU - Trudy F. C. Mackay AU - Robert R. H. Anholt AU - Rohan H.C. Palmer TI - Ibrutinib as a Potential Therapeutic for Cocaine Use Disorder AID - 10.1101/2021.02.05.21251228 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.05.21251228 4099 - http://medrxiv.org/content/early/2021/02/08/2021.02.05.21251228.short 4100 - http://medrxiv.org/content/early/2021/02/08/2021.02.05.21251228.full AB - Cocaine use presents a worldwide public health problem with high socioeconomic cost. Current treatments for cocaine use disorder (CUD) are suboptimal and rely primarily on behavioral interventions. To explore pharmaceutical treatments for CUD, we analyzed genome-wide gene expression data from publically availble human brain tissues (midbrain, hippocampus and prefrontal cortex neurons) from 71 individuals (mean age = 39.9, 100% male, 36 with CUD and 35 matched controls). We leveraged the L1000 database to investigate molecular associations between neuronal mRNA profiles from 825 repurposable compounds (e.g., FDA approved) with human CUD gene expression in the brain. We identified 16 compounds that were negatively associated with CUD gene expression patterns across all brain regions (padj < 0.05), all of which outperformed current targets undergoing clinical trials for CUD (all padj > 0.05). We tested the effectiveness of these compounds using independent transcriptome-wide in vitro (neuronal cocaine exposure; n=18) and in vivo (mouse cocaine self-administration; prefrontal cortex, hippocampus and midbrain; n = 12-15) datasets. Among these medications, Ibrutinib demonstrated negative associations with both neuronal cocaine exposure and mouse cocaine self-administration. To obtain experimental confirmation of therapeutic effects of Ibrutinib on CUD, we used the Drosophila melanogaster model, which enables highthroughput quantification of behavioral responses in defined genetic backgrounds and controlled environmental conditions. Ibrutinib altered cocaine-induced changes in startle response and reduced the occurrence of cocaine-induced seizures (n = 61-142 per group; sex: 51%female). Our results identify Ibrutinib, an FDA approved medication, as a potential therapeutic for cocaine neurotoxicity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the National Institute on Drug Abuse award DP1DA042103 (awarded to RHCP) and DA041613 (awarded to RRHA and TFCM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in this study is exempt from IRB oversight.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for drug discovery analyses are publicly available on Gene Expression Ominbus, Sequence Read Archive and Array Express.